IL1B and breast carcinoma: More specifically, IL-1β could directly promote epithelial–mesenchymal transition [76, 81], stimulate tumor cell adhesion to endothelial cells [82], activate matrix metalloproteinase (MMP) secretion [83], and mediate related-malignancy signaling pathways [84, 85], leading to pathological progression of breast cancers.